SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

TuHURA Reports Partial Responses in First Three IFx-2.0 Trial Patients

TuHURA reports partial responses in the first three patients in its IFx-2.0–Keytruda Merkel cell carcinoma trial.

HURA

Related stories